The great escape: tumour cell plasticity in resistance to targeted therapy

S Boumahdi, FJ de Sauvage - Nature reviews Drug discovery, 2020 - nature.com
The success of targeted therapies in cancer treatment has been impeded by various
mechanisms of resistance. Besides the acquisition of resistance-conferring genetic …

Lineage plasticity in cancer: a shared pathway of therapeutic resistance

Á Quintanal-Villalonga, JM Chan, HA Yu… - Nature reviews Clinical …, 2020 - nature.com
Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling

JM Chan, S Zaidi, JR Love, JL Zhao, M Setty… - Science, 2022 - science.org
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …

Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer

MK Bakht, Y Yamada, SY Ku, VB Venkadakrishnan… - Nature cancer, 2023 - nature.com
Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Genomic correlates of clinical outcome in advanced prostate cancer

W Abida, J Cyrta, G Heller, D Prandi… - Proceedings of the …, 2019 - National Acad Sciences
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

[HTML][HTML] The landscape of circular RNA in cancer

JN Vo, M Cieslik, Y Zhang, S Shukla, L Xiao, Y Zhang… - Cell, 2019 - cell.com
Circular RNAs (circRNAs) are an intriguing class of RNA due to their covalently closed
structure, high stability, and implicated roles in gene regulation. Here, we used an exome …

[HTML][HTML] A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization …

G Rindi, DS Klimstra, B Abedi-Ardekani, SL Asa… - Modern Pathology, 2018 - Elsevier
The classification of neuroendocrine neoplasms (NENs) differs between organ systems and
currently causes considerable confusion. A uniform classification framework for NENs at any …

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

KL Morel, AV Sheahan, DL Burkhart, SC Baca… - Nature cancer, 2021 - nature.com
Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

[HTML][HTML] Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study

R Aggarwal, J Huang, JJ Alumkal, L Zhang… - Journal of Clinical …, 2018 - ncbi.nlm.nih.gov
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine
prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor …

Genetics and biology of prostate cancer

G Wang, D Zhao, DJ Spring… - Genes & …, 2018 - genesdev.cshlp.org
Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …